F45 Training vs Uncommon Therapeutics

Side-by-side comparison of AI visibility scores, market position, and capabilities

Uncommon Therapeutics leads in AI visibility (27 vs 15)

F45 Training

UnknownFitness & Wellness

General

NYSE-listed global HIIT fitness franchise (FXLV) with 1,750+ locations in 63 countries; team-based 45-minute workouts with daily programmed content competing with Orangetheory for boutique fitness.

AI VisibilityBeta
Overall Score
D15
Category Rank
#741 of 1167
AI Consensus
52%
Trend
down
Per Platform
ChatGPT
25
Perplexity
7
Gemini
23

About

F45 Training is a global fitness franchise offering 45-minute team-based high-intensity interval training (HIIT) workouts that combine functional movement patterns with circuit-style training — rotating through hundreds of different workout formats to prevent adaptation and keep members motivated. Listed on NYSE (NYSE: FXLV) following its 2021 IPO at a peak market cap exceeding $1 billion, F45 was founded in 2013 in Sydney, Australia by Rob Deutsch and Luke Istomin, grew to 1,750+ locations in 63+ countries, and received $200 million in investment from actor Mark Wahlberg.

Full profile

Uncommon Therapeutics

EmergingHealthcare

General

Rare disease biotech developing polytherapy approach for Rett Syndrome (1 in 10,000 girls); founder-developed protocol validated through personal patient experience competing with Acadia Pharmaceuticals Daybue in Rett market.

AI VisibilityBeta
Overall Score
D27
Category Rank
#1121 of 1167
AI Consensus
67%
Trend
stable
Per Platform
ChatGPT
28
Perplexity
33
Gemini
36

About

Uncommon Therapeutics is a biotech company founded by Noah Auerhahn — directly inspired by his daughter's diagnosis with Rett Syndrome, a severe genetic neurological disease affecting approximately 1 in 10,000 girls — applying a polytherapy approach (combining multiple therapeutic agents targeting different disease mechanisms simultaneously) to develop treatments for serious neurological and rare diseases. After improving his daughter's quality of life through a personally developed polytherapy protocol, Auerhahn founded Uncommon Therapeutics to translate these insights into pharmaceutical products for the broader Rett Syndrome patient community.

Full profile

AI Visibility Head-to-Head

15
Overall Score
27
#741
Category Rank
#1121
52
AI Consensus
67
down
Trend
stable
25
ChatGPT
28
7
Perplexity
33
23
Gemini
36
23
Claude
22
12
Grok
33

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.